Humacyte, Inc. (HUMA)
The price, the headline numbers and the latest news, in one place.
Humacyte, Inc. (HUMA) Stock Price, Analysis & Data
| Bid | 0.45 |
| Market Cap | 167M |
| Revenue (ttm) | 2.12M |
| Net Income (ttm) | -96.7M |
| 2.47 | |
| -0.52 | |
| n/a | |
| -2.43 | |
| P/B (ttm) | 5.32 |
| P/S (ttm) | 78.77 |
| Earnings Date | Nov 12, 2026 |
| Ask | 0.76 |
| Volume | 13,522,774 |
| Avg. Volume (20D) | 10,907,582 |
| Open | 0.65 |
| Previous Close | 0.65 |
| Day's Range | 0.58 - 0.65 |
| 52-Week Range | 0.53 - 2.55 |
| Analyst | Buy |
| Price Target | 1.25 (108.33%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign...
Financial Performance
In 2025, Humacyte's revenue was 2.04M, an increase of undefined% compared to the previous year's 0. Earnings were -40.83M, a decrease of -72.54%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for HUMA stock is "Buy". The 12-month stock price forecast is 1.25, which is upside of 108.33% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $495K misses estimates by $0, with -4.26% YoY decline.
- EPS of -0.16 misses estimates by -0.06, with 33.33% YoY growth.
Analysts project revenue of ... Upgrade
2 weeks ago · Simply Wall St.
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In WomenHumacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplementa...